Summit Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Summit Therapeutics Inc's ROI in the second quarter of 2026?
Summit Therapeutics Inc recorded a cumulative net loss of $-856 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -160.48%.

Within the Healthcare sector 15 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2310 to 4149.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	44.83 %	25.74 %	28.18 %	25.75 %	127.42 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	649	581	689	215	276
Return On Investment (TTM)	-160.48 %	-273.92 %	-280.93 %	-296.78 %	-202.56 %
SMMT's Overall Ranking	# 4149	# 2310	# 2809	# 3996	# 3489
Seq. Investment Change TTM	21.15 %	14.57 %	23.75 %	-15.69 %	5.19 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-856	-1,206	-1,080	-922	-746

SMMT Company Profile >> Back to SMMT Roi Comparisons >> See Annual SMMT Return On Investment

Return On Investment SMMT's Ranking
Within:	No.
Industry	# 4
Sector	# 16
Overall	# 4149

Return On Investment Statistics
High	Average	Low
19.71 %	-106.75 %	-327.89 %
(Dec 31 2019)		(Dec 31 2023)

News about Summit Therapeutics Inc Return on Investment ROI

Augmenting NSCLC Treatment Ivonescimab Monotherapy Outperforms Pembrolizumab in Reducing Disease Progres...

September 9, 2024

: Recent advancements in immunotherapy have become pivotal in the treatment landscape for non-small cell lung cancer (NSCLC), particularly in patients presenting with programmed death-ligand 1 (PD-L1) positivity. Summit Therapeutics Inc. in its relentless pursuit of innovative oncology solutions, divulged promising data from the Phase III HARMONi-2 trial. The findings, presented at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, unveil the efficacy of ivonescimab, a bispecific antibody, in reducing disease progression or death in comparison to pembrolizumab monotherapy. Lung cancer remains a leading cause of cancer-related mortality globally, with NSCLC accounting for approximately 85% of all lung cancer cases. The overexpression of PD-L1 in certain patient subsets has directed the spotlight on immune checkpoint inhibitors such as pembrolizumab. However, the quest for more potent and targeted therapies continues. Ivonescimab, a novel bispecific antibody developed by Summit Therapeutics Inc. (NASDAQ: SMMT), represents a potential first-in-class therapeutic that combines the blockade of both PD-1/PD-L1 and VEGF pathways. This article delves into the comprehensive results from the primary analysis of the HARMONi-2 trial, which positions ivonescimab as a formidable contender in first-line treatment for advanced NSCLC with PD-L1 positivity.

Financial Statements
Summit Therapeutics Inc's II. Quarter Investments	$ 649 Millions	SMMT's Balance sheet
Summit Therapeutics Inc's II. Quarter Income	$ -216 Millions	Quarterly SMMT's Income Statement
SMMT's Income by Division		See SMMT's Income by Division

SMMT Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	679	394	183	1,121	90
Y / Y Investment Growth	72.16 %	115.72 %	-83.7 %	1139.76 %	6.52 %
Net Income in Millions	-1,080	-221	-615	-79	-89
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-159.09 %	-56.15 %	-336.54 %	-7.03 %	-98.01 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SMMT's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SMMT's Competitors
Subscribers only: Roi for Summit Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for SMMT's Customers

Other Ratios
SMMT's Roa	SMMT's Inventory Turnover Ratio	SMMT's Growth Rates	SMMT's Dividend Statistics
	SMMT's Profitability Ratios	SMMT's Asset Turnover Ratio	SMMT's Dividend Growth
SMMT's Roe	SMMT's Valuation Ratios	SMMT's Financial Strength Ratios	SMMT's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-30T13:42:11+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.